Author's response to reviews

Title: Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies

Authors:

Carin Jorup (carin.jorup@astrazeneca.com)
Thomas Bengtsson (thomas.bengtsson@i-mind.se)
Kerstin Strandgården (kerstin.strandgarden@astrazeneca.com)
Ulf Sjöbring (ulf.sjobring@astrazeneca.com)

Version: 4 Date: 19 March 2014

Author's response to reviews: see over
Attn: Ms Ma. Celine Zapanta on behalf of Dr Catia Cornacchia, Journal Editorial Office, BioMed Central

Re research article 1107660195937953: Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies

Dear Celine/ Dr Cornacchia

Thank you for giving us the opportunity for responding to your reviewers comments on our manuscript. We have made the following changes in response to the comments.

Reviewer 2 comments

Minor essentials:

Background and objectives:

- Glycopyrronium has only been approved as a once daily drug in Europe. There are ongoing phase 3 studies with twice daily administration, which were required by the FDA. Therefore, the sentence about glycopyrronium to be an approved twice daily β2-agonist is not appropriate.

- Olodaterol has been approved in a few European countries, if I’m not wrong in the Netherlands. Please, check it for accuracy about the statement related to this drug to be in late stage development.

Response: We have checked the regulatory status of a number of long-acting bronchodilators, as 2013/2014 has been a time of significant changes in this area, and have reworded the Background and objectives section accordingly, as below

Long-acting bronchodilators, whether administered twice-daily, such as the β2-agonists formoterol and salmeterol and the recently approved muscarinic antagonist aclidinium, or once-daily, such as indacaterol, tiotropium and the recently approved olodaterol, vilanterol, glycopyrronium and umeclidinium, are the mainstay of COPD treatment. Other long-acting, once-daily bronchodilators are also in late stage development, including abediterol.

We hope this satisfies your reviewers request for greater accuracy in these statements and look forward to publication of our manuscript in due course.

Thanks and regards

Carin